London, United Kingdom (PressExposure) February 02, 2012 -- GlobalData estimates that the global rhabdomyosarcoma therapeutics market was valued at $37.8m in 2011, and is forecast to grow at slow pace with a Compound Annual Growth Rate (CAGR) of 2.4% over the next seven years to reach $45.8m by 2019. This slow growth is primarily attributed to the fact that the patient population shows a moderate to lower growth in the US, the UK, France and Italy. However, Germany, Spain and Japan show a negative trend over the years
The rhabdomyosarcoma therapeutics market is relatively small compared to other cancers, and untapped opportunity exists for companies with novel approaches to systemic therapy plus local control and therapies with improved toxicity profiles.
The current competition in the global rhabdomyosarcoma therapeutics market is weak, as there is only one approved drug, vincristine, which is prescribed in combination with any of the five off-label drugs such as dactinomycin, doxorubicin, cyclophosphamide, ifosfamide and etoposide. These regimens have been moderately effective in the treatment of rhabdomyosarcoma. There is a need for more effective, targeted and tolerable therapies for rhabdomyosarcoma. Considerable opportunity exists for newer treatment options to meet the unmet need.
For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Rhabdomyosarcoma-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&Title=Pharmaceuticals_and_Healthca&ReportType=Industry_Report&CompanyID=pexpo
The rhabdomyosarcoma market is underserved by the currently followed drugs as there is no standard therapy for rhabdomyosarcoma. The only approved drug, vincristine, has been largely been used along with other off-label generic drugs. The rhabdomyosarcoma pipeline is strong, with all the molecules being first-in-class. These pipeline molecules may change the future treatment landscape for rhabdomyosarcoma. Some promising molecules in clinical development include Avastin (bevacizumab), IMC-A12 (cixutumumab), dasatinib, Torisel (temsirolimus) and TH-302. These are highly targeted therapies with low toxicity. These first-in-class molecules have distinct advantages over the currently used products in terms of better disease management.
GlobalData's analysis indicates that the unmet need for rhabdomyosarcoma treatment is high due to the lack of standardized treatment. The current drug regimens used in the treatment of rhabdomyosarcoma have good efficacy but low safety profiles. As a result, there is a need for drugs with novel mechanisms of action to treat the underlying cause of the disease. The future rhabdomyosarcoma therapeutics market will provide huge opportunities for new entrants due to two primary factors. There is a significant need to improve the outcome for high and intermediate risk patients and the increasing need of targeted therapies with novel mechanisms of action with improved safety and toxicity profiles.
GlobalData, the industry analysis specialist, has released its new report, "Rhabdomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Rhabdomyosarcoma Therapeutics market. The report identifies the key trends shaping and driving the global Rhabdomyosarcoma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Rhabdomyosarcoma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Rhabdomyosarcoma-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthca&CompanyID=pexpo
Visit our report store: http://www.globaldata.com/reportstore
For more details contact: firstname.lastname@example.org
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782